Surrozen, a biotech company focused on eye disease therapies, announced it will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The presentation will include a fireside chat discussing their Wnt signaling-based therapeutics aimed at treating sight-threatening ophthalmic conditions. Investors can access the webcast live or via replay on Surrozen's website. This event highlights Surrozen's ongoing development efforts and partnership with Boehringer Ingelheim, signaling progress in their clinical and commercial plans.
The Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) is rated Hold because of ongoing market risks despite outperforming peers like SPYI in flat market conditions and showing better drawdown management. The ETF benefits from premium harvesting...
Rentokil Initial PLC reported a 28.9% year-on-year increase in unique website visits in July, leading the pest control sector in traffic growth. This rise, highlighted by RBC Capital Markets, suggests a tentative recovery in demand after a slow sprin...
Bitcoin price rose 1.2% to around $63,650 after buyers defended support near $62,700, showing short-term momentum improvement. However, nearly $390 million exited US spot Bitcoin ETFs last week, indicating cautious institutional demand. Key resistanc...
Kratos Defense & Security Solutions reported strong second-quarter results and raised its guidance for 2026, signaling confidence in continued growth. The company's backlog reached $2.08 billion, supported by new facilities aimed at turbojet engine p...
Delta Air Lines is re-establishing a strong presence in Texas by focusing on Austin after closing its Dallas/Fort Worth hub in 2005. The airline announced new flights from Austin to Paris and San Diego, citing Austin's booming economy and global conn...
